|1.||Yang, Xian: 3 articles (11/2013 - 07/2009)|
|2.||Hu, Xiao-Dong: 3 articles (11/2013 - 07/2009)|
|3.||Suzuki, Miki: 3 articles (06/2013 - 04/2010)|
|4.||Takeda, Atsushi: 3 articles (06/2013 - 04/2010)|
|5.||Bausch, Suzanne B: 3 articles (07/2010 - 12/2004)|
|6.||Suo, Zhan-Wei: 2 articles (11/2013 - 05/2011)|
|7.||Sakamoto, Kazuhiro: 2 articles (06/2013 - 01/2012)|
|8.||Tamano, Haruna: 2 articles (06/2013 - 01/2012)|
|9.||Yokogoshi, Hidehiko: 2 articles (06/2013 - 01/2012)|
|10.||Oku, Naoto: 2 articles (01/2012 - 04/2010)|
07/01/2010 - "We showed previously that electrographic seizures involving dentate granule cells in organotypic hippocampal slice cultures were dramatically reduced following chronic treatment with the NR2B-selective antagonist, Ro25,6981, but were increased following chronic treatment with the high-affinity competitive antagonist, D(-)-2-amino-5-phosphonopentanoic acid (D-APV). "
07/01/2010 - "Initial experiments revealed a lack of an association between miniature excitatory postsynaptic current (mEPSC) measures and seizures suggesting that shifts in mEPSC were unlikely to account for the differential effects of D-APV and Ro25,6981 on seizures. "
10/01/2006 - "Changes were more profound and qualitatively different in TTX- compared with D-APV-treated cultures, consistent with the dramatic effects of TTX treatment on seizure expression. "
10/01/2006 - "Granule cell field potential recordings in physiological buffer revealed spontaneous electrographic seizures in 83% of TTX-, 9% of D-APV-, but 0% of vehicle-treated cultures. "
04/22/1988 - "In contrast, D(-)APV had no effect on KA-induced wet dog shakes or on behavioral seizures. "
03/01/2003 - "Spinal pretreatment of D-APV or low doses of MS partially reduced visceral pain behaviors in this model. "
07/01/2009 - "Inhibition of spinal NMDARs with D-APV completely eliminated the CFA-induced increase in NR1 immunoreactive density at synapses, and direct application of NMDA onto the spinal cord of naïve mice mimicked the effects of CFA, suggesting the importance of NMDARs activity in regulating the synaptic content of NR1 during inflammatory pain. "
07/01/2001 - "The carrageenan model of inflammatory pain has been and still is widely used as is the NMDA receptor antagonist 2-amino-5-phosphonopentanoic acid (AP5) to investigate NMDA receptor function. "
01/01/1998 - "The purpose of this study was to examine the effect of intrathecal (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine (MK-801), a noncompetitive NMDA receptor antagonist, 2-amino-5-phosphonovaleric acid (AP5), a competitive NMDA receptor antagonist, and N-G-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, on pain behaviors in a rat model of postoperative pain. "
03/01/2003 - "Intrathecal coadministration of D-APV and morphine is maximally effective in a rat experimental pancreatitis model."
03/01/2003 - "Spinal administration of combined doses of NMDA receptor antagonist, D-APV, and MS reversed three behavioral responses to induction of an acute pancreatitis model. "
03/01/2003 - "The current study examined spinal coadministration of low doses of NMDA receptor antagonist, D-(-)-2-Amino-5-phosphonovalerate (D-APV), and mu-opioid receptor agonist, morphine sulfate (MS), in reducing visceral nociception using an acute bradykinin induced pancreatitis model in rats. "
05/28/1993 - "Bath application of D-APV (30 microM) prevented the significant reduction in the AD onset latency to the second hypoxia, but had no significant effect on the AD amplitude and duration. "
05/28/1993 - "The hypoxia-induced decrease in [Ca2+]o was not altered after addition of D-APV to the bathing medium. "
01/01/2003 - "The selected NMDA receptor antagonists 2-amino-5-phosphonopentanoate (AP5) added in the perfusion medium after the anoxia, did not eliminate the neuroprotective effect of CRF."
11/01/1991 - "2-APV and DGAMS are superior to MK-801 in preventing hypoxia-induced injury to developing neurons in vitro."
11/01/1987 - "Cultures exposed to hypoxia for 8 hr showed by the following day widespread neuronal injury, which was substantially attenuated by addition of the specific N-methyl-D-aspartate (NMDA) receptor antagonist 2-amino-5-phosphonovalerate (APV). "
09/19/1994 - "The PIP was not affected by 2-amino-5-phosphonovalerate (APV) administered via microdialysis at 7 h post-ischemia. "
08/04/1986 - "D-APV reduced the extracellular accumulation of all measured purine catabolites during ischemia/reflow and improved to some extent the recovery of the striatal electroencephalographic activity in the majority of the animals. "
07/01/2010 - "The [Ca(2+)]i overload produced by acidosis and ischemia was not blocked by tetrodotoxin, 2-amino-5-phosphonopentanoic acid or nifedipine. "
04/01/1991 - "Blockade of N-methyl-D-aspartate-sensitive excitatory amino acid receptors with 2-amino-5-phosphonovalerate reduces ischemia-evoked calcium redistribution in rabbit hippocampus."
04/01/1991 - "To evaluate the participation of excitatory amino acid receptors sensitive to N-methyl-D-aspartate (NMDA) in ischemia-evoked redistribution of Ca2+ ions from the extra- to the intracellular compartment of the hippocampus, 2-amino-5-phosphonovalerate (APV), a specific antagonist of NMDA receptors, was administered to the rabbit hippocampus through a dialysis probe before, during, and after complete reversible 15-min cerebral ischemia. "
|2.||Morphine (MS Contin)
|6.||Dizocilpine Maleate (Dizocilpine)
|7.||NG-Nitroarginine Methyl Ester (L-NAME)
|8.||Nitric Oxide Synthase (NO Synthase)
|9.||mu Opioid Receptors (mu Opioid Receptor)